Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factors associated with long-term progression or stability in primary open-angle glaucoma.

W C Stewart1, A E Kolker, E D Sharpe

  • 1Pharmaceutical Research Corporation, Charleston, South Carolina 29412-2464, USA.

American Journal of Ophthalmology
|October 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial (1).

Journal of glaucoma·2009
Same author

Diagnosis and treatment of cyclodialysis clefts.

Journal of glaucoma·2009
Same author

Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma.

European journal of ophthalmology·2008
Same author

Mean intraocular pressure and progression based on corneal thickness in patients with ocular hypertension.

Eye (London, England)·2007
Same author

Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination.

European journal of ophthalmology·2005
Same author

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.

Eye (London, England)·2005

Identifying long-term risk factors for primary open-angle glaucoma (POAG) progression is crucial. While lowering intraocular pressure (IOP) helps, it doesn't uniformly prevent POAG worsening, and other risk factors don't refine IOP targets.

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Clinical Trials

Background:

  • Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness.
  • Long-term management strategies aim to prevent disease progression and preserve visual function.
  • Understanding risk factors is essential for personalized treatment approaches.

Purpose of the Study:

  • To identify long-term risk factors associated with disease progression or stability in patients diagnosed with primary open-angle glaucoma.
  • To evaluate the effectiveness of intraocular pressure (IOP) management in preventing POAG progression.

Main Methods:

  • Retrospective analysis of consecutively reviewed patients with POAG for at least 5 years.
  • Multicenter trial evaluating historical and clinical factors for association with glaucoma stability or progression.

Related Experiment Videos

  • Comparison of intraocular pressure (IOP) levels and variability between stable and progressed groups.

    • Main Results:

    • Of 218 patients, 34 progressed and 184 remained stable.
    • Progressed group had higher mean IOP (19.5 mmHg vs. 17.2 mmHg, P=.001) and greater IOP variability (SD 5.1 mmHg vs. 3.9 mmHg, P=.012).
    • Risk factors for progression included larger cup-to-disk ratio, more medications, older age, and worse visual acuity.

    Conclusions:

    • Lowering intraocular pressure is important for managing primary open-angle glaucoma, but not uniformly effective in preventing long-term progression.
    • Identified risk factors do not refine specific IOP targets for preventing glaucoma worsening.
    • Further research may be needed to optimize POAG management strategies.